“…Limited data on the burden of high SABA use and considerable variability in the definition of SABA 'overuse' [17,[43][44][45] have made comparisons with previous studies and regions challenging. In the SABINA program [21], the definition of high SABA use has been standardized across studies, enabling comparison and harmonization of results across geographies. Table 7 continued BDP beclomethasone dipropionate, BTS British Thoracic Society, CI confidence interval, COPD chronic obstructive pulmonary disease, PDC proportion of days covered, ICS inhaled corticosteroids, IMD Index of Multiple Deprivation, IRR incident rate ratio, N/A not applicable, SABA short-acting b 2 -agonists a The model was adjusted by all the variables shown in the table b Low use: 0-2 SABA canisters/year; high use: C 3 SABA canisters/year Emerging data from more than 1 million patients in the SABINA program reveal that high SABA use is also prevalent in other European countries, such as Sweden (30%), Germany (16%), Spain (29%), and Italy (9%), and is found across asthma severities [46].…”